Asia
The drug, a checkpoint inhibitor, met the primary endpoint of improved progression-free survival at the planned interim analysis.
Coherus BioSciences, Inc. announced the Company has entered into a licensing agreement with Innovent Biologics, Co., Ltd.,, a leading biopharmaceutical company headquartered in China, to commercialize Innovent’s biosimilar candidate to Avastin® in the United States and Canada.
Over the past year, the company strived to transform itself into becoming a frontrunner in multiple areas, including cell and gene therapies.
PhoreMost and Otsuka Pharmaceutical Co. entered into a multi-project collaboration to seek out disease-relevant pathways that can be exploited for the development of gene therapies to treat different illnesses.
Companies are cutting the price of some medications by an average of 53% in order to qualify for the bulk-buy program in China, Reuters reported.
Celltrion’s chairman Jung Jin Seo announced at last week’s JP Morgan Healthcare Conference the company’s strategy for the next decade.
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities
There were plenty of clinical trial announcements this week. Here’s a look.
TCG Lifesciences, a company promoted by New York based Purnendu Chatterjee Group, has announced the induction of Chris Senanayake, as Chief Scientific Officer responsible for delivering highest quality scientific solutions and innovations to its global client base.
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
PRESS RELEASES